Literature DB >> 31219196

Why maximum tolerated dose?

Hans G Stampfer1, Genevieve M Gabb2, Simon B Dimmitt3,4.   

Abstract

A long-established approach to the pharmacological treatment of disease has been to start low and go slow. However, clinicians often prescribe up to maximum tolerated dose (MTD), especially when treating acute and more severe disease, without evidence to show that MTD is more likely to improve outcomes. Cardiovascular guidelines for some indications advocate MTD even in prevention, for example hypercholesterolaemia, without compelling evidence of better outcomes. This review explores the origins and potential problems of prescribing medications at MTD. Oral effective dose 50 (ED50) may be a useful guide for balancing efficacy and safety.
© 2019 The British Pharmacological Society.

Keywords:  clinical pharmacology; dosing outcomes; effective dose 50; maximum tolerated dose

Mesh:

Substances:

Year:  2019        PMID: 31219196      PMCID: PMC6783596          DOI: 10.1111/bcp.14032

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  47 in total

1.  High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.

Authors:  Robert A Terkeltaub; Daniel E Furst; Katherine Bennett; Karin A Kook; R S Crockett; Matthew W Davis
Journal:  Arthritis Rheum       Date:  2010-04

2.  Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses.

Authors:  Rajesh R Tampi; Deena J Tampi; Silpa Balachandran; Shilpa Srinivasan
Journal:  Ther Adv Chronic Dis       Date:  2016-07-15       Impact factor: 5.091

Review 3.  Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.

Authors:  Vijaya M Musini; Mark Nazer; Ken Bassett; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2014-05-29

4.  Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population.

Authors:  David Garcia; Susan Regan; Mark Crowther; Robert A Hughes; Elaine M Hylek
Journal:  Chest       Date:  2005-06       Impact factor: 9.410

5.  Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis.

Authors:  Tejas K Patel; Parvati B Patel
Journal:  Eur J Clin Pharmacol       Date:  2018-03-19       Impact factor: 2.953

Review 6.  How do we improve patient compliance and adherence to long-term statin therapy?

Authors:  Patricia Maningat; Bruce R Gordon; Jan L Breslow
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

Review 7.  Dose response and dose equivalence of antipsychotics.

Authors:  John M Davis; Nancy Chen
Journal:  J Clin Psychopharmacol       Date:  2004-04       Impact factor: 3.153

8.  Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

Authors:  Jeffrey H Meyer; Alan A Wilson; Sandra Sagrati; Doug Hussey; Anna Carella; William Z Potter; Nathalie Ginovart; Edgar P Spencer; Andy Cheok; Sylvain Houle
Journal:  Am J Psychiatry       Date:  2004-05       Impact factor: 18.112

9.  Differing response to antipsychotic therapy in schizophrenia: pharmacogenomic aspects.

Authors:  Manfred Ackenheil; Klaus Weber
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

10.  Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.

Authors:  Ricky D Turgeon; Michael R Kolber; Peter Loewen; Ursula Ellis; James P McCormack
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

View more
  3 in total

Review 1.  Why maximum tolerated dose?

Authors:  Hans G Stampfer; Genevieve M Gabb; Simon B Dimmitt
Journal:  Br J Clin Pharmacol       Date:  2019-07-22       Impact factor: 4.335

2.  Identifying potential natural inhibitors of Brucella melitensis Methionyl-tRNA synthetase through an in-silico approach.

Authors:  Adekunle Babajide Rowaiye; Akwoba Joseph Ogugua; Gordon Ibeanu; Doofan Bur; Mercy Titilayo Asala; Osaretin Benjamin Ogbeide; Emmanuella Oshiorenimeh Abraham; Hamzah Bundu Usman
Journal:  PLoS Negl Trop Dis       Date:  2022-03-21

3.  Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach.

Authors:  Farshad Moradi Kashkooli; M Soltani
Journal:  Sci Rep       Date:  2021-11-02       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.